Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a biotechnology company specializing in innovative multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), has announced its participation in the 24th Annual Needham Virtual Healthcare Conference.

The company's President and CEO, Bill Lundberg, M.D., will engage in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. ET. Investors and interested parties can access the live webcast through the Investors section of the Merus website, where the presentation recording will remain available for a time following the event.

News Market Reaction – MRUS

-5.92%

-5.92% Session move

In the trading session that priced this news, MRUS declined 5.92%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics^®, Triclonics^® and ADClonics^®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025 at 8:45 a.m. ET.

The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.

Multiclonics^®, Biclonics^®, Triclonics^® and ADClonics^® are registered trademarks of Merus N.V.

Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
s.spear@merus.nl

Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
k.farren@merus.nl

FAQ

When is Merus (MRUS) presenting at the Needham Healthcare Conference 2025?

Merus will present on Tuesday, April 8, 2025, at 8:45 a.m. ET during the 24th Annual Needham Virtual Healthcare Conference.

How can investors watch the Merus (MRUS) Needham Conference presentation?

Investors can watch the presentation live through the webcast available on the Investors page of Merus' website, where it will also be archived for time.

What type of antibody technologies does Merus (MRUS) develop?

Merus develops innovative, full-length multispecific antibodies and antibody drug conjugates, including Biclonics®, Triclonics® and ADClonics®.

Who will represent Merus (MRUS) at the 2025 Needham Healthcare Conference?

Bill Lundberg, M.D., President and Chief Executive Officer of Merus, will represent the company in a fireside chat.